EBS Emergent BioSolutions Inc

NYSE
$4.59

Emergent BioSolutions Inc (EBS) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.75 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.9% since its last earnings release on August 5, 2026.

Emergent BioSolutions Reported Earnings
Wednesday, August 5, 2026 · 4:07 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.75)
Rev est $128.6M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.75

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Emergent BioSolutions Inc

Emergent BioSolutions Inc is a specialty biopharmaceutical company operating in two divisions: Biodefense and Biosciences. Its products include BioThrax, BAT, Anthrasil, VIGIV, RSDL, NuThrax, PreviThrax and GC-072.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow